Vildagliptin
General
Type : Drug,Pyrrolidine,Gliptin,Adamantyl
Chemical_Nomenclature : (2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile
Canonical SMILES : C1CC(N(C1)C(=O)CNC23CC4CC(C2)CC(C4)(C3)O)C#N
InChI : InChI=1S\/C17H25N3O2\/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16\/h12-14,19,22H,1-8,10-11H2\/t12?,13?,14-,16?,17?\/m0\/s1
InChIKey : SYOKIDBDQMKNDQ-XWTIBIIYSA-N
Other name(s) : NVP-LAF237,Galvus,Xiliarx,Jalra
MW : 303.39
Formula : C17H25N3O2
CAS_number : 274901-16-5
PubChem : 6918537
UniChem : SYOKIDBDQMKNDQ-XWTIBIIYSA-N
IUPHAR : 6310
Wikipedia : Vildagliptin
Target
Families : Vildagliptin ligand of proteins in family: DPP4N_Peptidase_S9
Stucture :
Protein : human-DPP4
References (12)
| Title : Effects of Vildagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on the Parameters of Glucose Metabolism and the Cardio-Ankle Vascular Index in Individuals with Type 2 Diabetes - Nagayama_2024_J.Clin.Med_13_ |
| Author(s) : Nagayama D , Kawana H , Watanabe Y , Horikawa O , Ohira M , Saiki A |
| Ref : J Clin Med , 13 : , 2024 |
| Abstract : Nagayama_2024_J.Clin.Med_13_ |
| ESTHER : Nagayama_2024_J.Clin.Med_13_ |
| PubMedSearch : Nagayama_2024_J.Clin.Med_13_ |
| PubMedID: 38256615 |
| Title : Insight into the Role of Active Site Protonation States and Water Molecules in the Catalytic Inhibition of DPP4 by Vildagliptin - Corredor_2023_J.Chem.Inf.Model__ |
| Author(s) : Corredor JD , Febres-Molina C , Jana GA , Jimenez VA |
| Ref : J Chem Inf Model , : , 2023 |
| Abstract : Corredor_2023_J.Chem.Inf.Model__ |
| ESTHER : Corredor_2023_J.Chem.Inf.Model__ |
| PubMedSearch : Corredor_2023_J.Chem.Inf.Model__ |
| PubMedID: 36757339 |
| Title : Vildagliptin restores cognitive function and mitigates hippocampal neuronal apoptosis in cisplatin-induced chemo-brain: Imperative roles of AMPK\/Akt\/CREB\/ BDNF signaling cascades - Mahmoud_2023_Biomed.Pharmacother_159_114238 |
| Author(s) : Mahmoud AMA , Mantawy EM , Wahdan SA , Ammar RM , El-Demerdash E |
| Ref : Biomed Pharmacother , 159 :114238 , 2023 |
| Abstract : Mahmoud_2023_Biomed.Pharmacother_159_114238 |
| ESTHER : Mahmoud_2023_Biomed.Pharmacother_159_114238 |
| PubMedSearch : Mahmoud_2023_Biomed.Pharmacother_159_114238 |
| PubMedID: 36640673 |
| Title : Vildagliptin-Derived Dipeptidyl Peptidase 9 (DPP9) Inhibitors: Identification of a DPP8\/9-Specific Lead - Benramdane_2022_ChemMedChem__e202200097 |
| Author(s) : Benramdane S , De Loose J , Beyens O , Van Rymenant Y , Vliegen G , Augustyns K , De Winter H , De Meester I , Van der Veken P |
| Ref : ChemMedChem , :e202200097 , 2022 |
| Abstract : Benramdane_2022_ChemMedChem__e202200097 |
| ESTHER : Benramdane_2022_ChemMedChem__e202200097 |
| PubMedSearch : Benramdane_2022_ChemMedChem__e202200097 |
| PubMedID: 35760756 |
| Title : Covalent Inhibition Mechanism of Antidiabetic DrugsVildagliptin vs Saxagliptin - Wang_2019_ACS.Catalysis_9_2292 |
| Author(s) : Wang YH , Zhang F , Diao H , Wu R |
| Ref : ACS Catal , 9 :2292 , 2019 |
| Abstract : Wang_2019_ACS.Catalysis_9_2292 |
| ESTHER : Wang_2019_ACS.Catalysis_9_2292 |
| PubMedSearch : Wang_2019_ACS.Catalysis_9_2292 |
| PubMedID: |
| Title : A comparative study of the binding properties, dipeptidyl peptidase-4 (DPP-4) inhibitory activity and glucose-lowering efficacy of the DPP-4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice - Berger_2018_Endocrinol.Diabetes.Metab_1_e00002 |
| Author(s) : Berger JP , SinhaRoy R , Pocai A , Kelly TM , Scapin G , Gao YD , Pryor KAD , Wu JK , Eiermann GJ , Xu SS , Zhang X , Tatosian DA , Weber AE , Thornberry NA , Carr RD |
| Ref : Endocrinol Diabetes Metab , 1 :e00002 , 2018 |
| Abstract : Berger_2018_Endocrinol.Diabetes.Metab_1_e00002 |
| ESTHER : Berger_2018_Endocrinol.Diabetes.Metab_1_e00002 |
| PubMedSearch : Berger_2018_Endocrinol.Diabetes.Metab_1_e00002 |
| PubMedID: 30815539 |
| Gene_locus related to this paper: human-DPP4 |
| Title : A Comparative Study of the Binding Modes of Recently Launched Dipeptidyl Peptidase IV Inhibitors in the Active Site - Nabeno_2013_Biochem.Biophys.Res.Commun_434_191 |
| Author(s) : Nabeno M , Akahoshi F , Kishida H , Miyaguchi I , Tanaka Y , Ishii S , Kadowaki T |
| Ref : Biochemical & Biophysical Research Communications , 434 :191 , 2013 |
| Abstract : Nabeno_2013_Biochem.Biophys.Res.Commun_434_191 |
| ESTHER : Nabeno_2013_Biochem.Biophys.Res.Commun_434_191 |
| PubMedSearch : Nabeno_2013_Biochem.Biophys.Res.Commun_434_191 |
| PubMedID: 23501107 |
| Gene_locus related to this paper: human-DPP4 |
| Title : Vildagliptin: a review of its use in type 2 diabetes mellitus - Keating_2010_Drugs_70_2089 |
| Author(s) : Keating GM |
| Ref : Drugs , 70 :2089 , 2010 |
| Abstract : Keating_2010_Drugs_70_2089 |
| ESTHER : Keating_2010_Drugs_70_2089 |
| PubMedSearch : Keating_2010_Drugs_70_2089 |
| PubMedID: 20964454 |
| Title : Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes - Gupta_2009_Curr.Drug.Targets_10_71 |
| Author(s) : Gupta R , Walunj SS , Tokala RK , Parsa KV , Singh SK , Pal M |
| Ref : Curr Drug Targets , 10 :71 , 2009 |
| Abstract : Gupta_2009_Curr.Drug.Targets_10_71 |
| ESTHER : Gupta_2009_Curr.Drug.Targets_10_71 |
| PubMedSearch : Gupta_2009_Curr.Drug.Targets_10_71 |
| PubMedID: 19149538 |
| Title : Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes - Ahren_2009_J.Clin.Endocrinol.Metab_94_1236 |
| Author(s) : Ahren B , Schweizer A , Dejager S , Dunning BE , Nilsson PM , Persson M , Foley JE |
| Ref : J Clinical Endocrinology Metab , 94 :1236 , 2009 |
| Abstract : Ahren_2009_J.Clin.Endocrinol.Metab_94_1236 |
| ESTHER : Ahren_2009_J.Clin.Endocrinol.Metab_94_1236 |
| PubMedSearch : Ahren_2009_J.Clin.Endocrinol.Metab_94_1236 |
| PubMedID: 19174497 |
| Title : Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects - He_2008_J.Clin.Pharmacol_48_85 |
| Author(s) : He YL , Ligueros-Saylan M , Sunkara G , Sabo R , Zhao C , Wang Y , Campestrini J , Pommier F , Dole K , Marion A , Dole WP , Howard D |
| Ref : Journal of Clinical Pharmacology , 48 :85 , 2008 |
| Abstract : He_2008_J.Clin.Pharmacol_48_85 |
| ESTHER : He_2008_J.Clin.Pharmacol_48_85 |
| PubMedSearch : He_2008_J.Clin.Pharmacol_48_85 |
| PubMedID: 17986525 |
| Title : Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile) - Brandt_2005_Biochem.Pharmacol_70_134 |
| Author(s) : Brandt I , Joossens J , Chen X , Maes MB , Scharpe S , De Meester I , Lambeir AM |
| Ref : Biochemical Pharmacology , 70 :134 , 2005 |
| Abstract : Brandt_2005_Biochem.Pharmacol_70_134 |
| ESTHER : Brandt_2005_Biochem.Pharmacol_70_134 |
| PubMedSearch : Brandt_2005_Biochem.Pharmacol_70_134 |
| PubMedID: 15907807 |